Six-person Cornell spinout raises $90M for prostate cancer drugs - Convergent Therapeutics

Skip to content

Home
About Us
Our Science
News & Media

Convergent Therapeutics, Inc. is a biotechnology company focused on developing next-generation targeted radiotherapies to treat cancer.

©2024 Convergent Therapeutics, Inc. All rights reserved. | Privacy Policy | Cookie Settings

CONNECT

CONTACT

©2024 Convergent Therapeutics, Inc.
All rights reserved. | Privacy Policy | Cookie Settings